Prostate cancer is the most common cancer in men, but behavior varies widely — some tumors grow slowly and need minimal treatment, while others are aggressive and require immediate action. Treatment options include surgery, radiation, hormone therapy, and newer targeted drugs. Active surveillance is now standard for low-risk disease.
What's actually going on in research
Trials are testing PARP inhibitors for tumors with DNA-repair mutations, radioligand therapies that deliver radiation directly to cancer cells, and immunotherapies that train the immune system to attack prostate cancer. Researchers are also studying better ways to predict which tumors will stay slow-growing and which will spread.
Radioligand therapy
Drugs like lutetium-177-PSMA-617 attach to prostate cancer cells and deliver targeted radiation. FDA-approved in 2022, this approach is now being tested earlier in disease and in combination with other treatments.
PARP inhibitors
Olaparib and rucaparib target tumors with BRCA or other DNA-repair gene mutations. Trials are testing whether they work in earlier stages and in more types of mutations.
Precision radiation
Studies are refining radiation techniques to reduce side effects while treating cancer more effectively. New imaging helps identify exactly where tumors are spreading.
What to know before you search
Eligibility depends on cancer stage, PSA level, Gleason score, prior treatments, and genetic markers like BRCA mutations.
What types of trials are currently open
- Treatment trials — Testing new drugs or drug combinations, often for metastatic prostate cancer that has stopped responding to hormone therapy.
- Radiation trials — Comparing different radiation techniques or testing whether radiation can be skipped in low-risk cases.
- Active surveillance studies — Following men with low-risk prostate cancer closely to determine when treatment becomes necessary.
- Prevention trials — Testing whether drugs or lifestyle changes can prevent prostate cancer or delay its progression in high-risk men.
- Biomarker studies — Using blood tests, imaging, or tumor samples to predict which cancers will grow aggressively and which treatments will work best.
Recently added Prostate Cancer trials
Nerve-SPARing Robotic Prostatectomy: The Impact of Patient Baseline Profiles on Erectile Function
1. STUDY PURPOSE: Robot-assisted surgery for prostate cancer aims to remove the tumor while preserving the delicate nerves that control erections (called "nerve-sparing" surgery). Even with advanced robotics, some patients still experience erectile dysfunction after surgery. Recovery depends not only on the surgeon's technique (one-sided or two-sided nerve sparing), but also on patient unique baseline health profile. The present study aims to analyze how patient age, health history (like diabetes or high blood pressure), and pre-surgery sexual function affect recovery. Doctors will use this data to create a personalized prediction tool (a nomogram) to better advise future patients. 2. STUDY DESIGN: This study will not change, delay, or interfere with participants' standard medical care. The surgeon will choose the safest surgical path to treat cancer. To ensure the highest quality and eliminate surgical bias, all operations will be performed by a single, highly experienced robotic surgeon who has completed over 5,000 procedures. If patients agree to join, participants will be asked to fill out private health questionnaires at four specific time points: Baseline: Before surgery. Follow-ups: At 3 months, 6 months, and 12 months after surgery. 3. STUDY MEASUREMENTS: Erectile Function: Patient ability to achieve a functioning erection (with or without the help of medications like Viagra) at the 12-month mark compared to patient baseline. Oncological Safety: Routine checks of patient PSA levels and surgical margins to guarantee that sparing the nerves did not compromise cancer cure
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.
Find Prostate Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.